Consistently, neither aPL positivity nor serum levels of aPL, either at baseline or post-treatment, differed between LN patients with CKD stage 1–2 and patients with CKD stage ≥3 at the last follow-up (p = NS). Here, FASLG is linked to lobular neoplasia.